ArticleCirculation2026
miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction.
Article in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Epigenetic Mechanisms in Sepsis-Induced Cardiomyopathy: From Pathophysiology to Therapeutic Targets.International journal of molecular sciences · 2026Review
- Protection against postoperative atrial fibrillation via antiplatelet aggregation induced by remote ischemic preconditioning during off-pump coronary artery bypass grafting.Basic research in cardiology · 2026Article
- Metabolic Reprogramming-Driven Cardiovascular Immune Damage: From Glyco-Lipotoxicity and Epigenetic Memory to Multidimensional Cross-Organ Communication Networks.International journal of molecular sciences · 2026Review
- Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell-Based Therapies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
- Inhalable extracellular vesicles as cell-free therapeutics for chronic respiratory disease.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundEmergency myelopoiesis by bone marrow hematopoietic stem and progenitor cells (HSPCs) exacerbates disease pathology in various chronic diseases, including myocardial infarction (MI) and atherosclerosis. However, the mechanisms triggering myelopoiesis in the bone marrow after a distant organ injury, such as MI, remain unknown.
methodsWe ligated the left descending coronary artery to induce MI in mice. Platelet-derived extracellular vesicles (pEVs) were detected and enumerated in mice and patients with MI using NanoSight, ImageStream, and flow cytometry. microRNA in pEVs was quantified using a microRNA array. We used parabiosis, flow cytometry, adoptive transfer experiments, and transgenic mice to assess the effects of pEVs and microRNA on HSPC lineage commitment and inflammatory cell generation. In addition, we carried out RNA sequencing, luciferase assay, lentivirus-mediated in vivo gene overexpression, and echocardiography to evaluate the merit of lactoferrin/lactotransferrin in post-MI pathogenesis.
resultsIn this study, we demonstrate that patients and mice with MI and mice with hindlimb ischemia exhibit an increased number of circulating pEVs, which, in turn, augment HSPC number and proliferation in the bone marrow, leading to inflammatory myeloid cell generation and disease progression. S100A8/9 (S100 calcium-binding protein A8/A9), an alarmin complex produced by cardiomyocytes after MI, induced pEV secretion. In vivo and in vitro inhibition of platelet activation and exocytosis, and HSPC endocytosis, markedly lessened the production of pEV, HSPC proliferation, and myeloid cell generation in emergency hematopoiesis. A microRNA array revealed that pEVs isolated after MI had elevated cargo levels of miR-499 and miR-184, which were enriched in reticulated platelets after MI. miR-499 and miR-184 overexpression in mouse and human HSPCs resulted in enhanced hematopoiesis and myelopoiesis. miR-499-deficient pEVs were inefficient in stimulating emergency myelopoiesis and inducing cardiac remodeling after MI. RNA sequencing analysis, luciferase assay, and lentivirus-mediated in vivo gene overexpression demonstrated that miR-499 bound to the 3' region of lactoferrin/lactotransferrin in HSPC to downregulate this gene, promoting myelopoiesis and unleashing inflammation.
conclusionsOur study suggests that pEVs generated after MI induce HSPC proliferation and inflammatory cell generation. These discoveries uncover several therapeutic targets to reduce cardiac inflammation and remodeling after MI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.